NEW YORK, July 27, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Tokai Pharmaceuticals, Inc. ("Tokai" or the "Company") (NASDAQ: TKAI). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at [email protected] or 212-697-6484.
The investigation concerns whether Tokai and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 26, 2016, Tokai announced that it would be concluding its late-stage trial of galeterone, its potential prostate cancer therapy. Tokai explained that it did not think the phase 3 study would meet the primary endpoint. Following this announcement Tokai's stock price dropped, damaging investors.
If you purchased Tokai shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!tkai/wnom2. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC